Cemiplimab and cetuximab before surgery for mouth or throat cancer
Treatments studied
Part of Cancer, Mouth & dental clinical trials.
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer that has come back in the same area (mouth or throat) after initial treatment with surgery and radiation.
- Your throat cancer must not be caused by HPV (human papillomavirus).
- You are able to have surgery to remove the cancer.
- Your cancer came back at least 3 months after finishing your last treatment.
- You are willing to have a biopsy (tissue sample) before and during treatment for research.
- You have good organ function (kidneys, liver, and blood counts) and an ECOG score of 0 or 1, meaning you are fully active or only slightly limited.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) before and after surgery for people whose mouth or throat cancer has returned after previous treatment. The goal is to see if this approach can help shrink or control the cancer and improve outcomes.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This trial tests a combination of two targeted drugs (an immunotherapy and an EGFR inhibitor) given before surgery to shrink locally advanced skin cancer and potentially make surgery easier or more successful. It may help people whose skin cancer is hard to treat with surgery alone.
Hear when a new Locally Recurrent Oral Cavity Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.